The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Decision on EU marketing authorisation for this population expected by September 2024
Subscribe To Our Newsletter & Stay Updated